Observational studyPeerJ2026
Targeted metabolomic profiling and machine learning-based prediction models for persistent atrial fibrillation: a multi-center observational study.
Observational study in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF), one of the most common cardiac arrhythmias worldwide, carries a high risk of severe complications. Patients diagnosed with paroxysmal atrial fibrillation (PAF) may progress to persistent atrial fibrillation (PerAF) following a period of time. This study aimed to identify metabolites associated with PerAF using machine learning (ML) and predict the probability of PAF progressing to PerAF, enabling the adjustment of subsequent treatments in clinical practice. Methods: AF patients without any anticoagulant therapy within the last 7 days were enrolled between July 2020 and July 2022 at two hospitals in China. Targeted metabolomic profiling was performed on the participating patients' plasma. Differential metabolites and clinical features were identified through univariate and multivariate analyses. Patients were divided into discovery and validation cohorts (70%:30%). Four ML models (logistic regression, random forest, XGBoost, and LightGBM) were developed for PerAF prediction. Model predictive performance was measured mainly using the area under the curve (AUC). Results: One hundred patients (65 PerAF, 35 PAF) were enrolled. Eight metabolites (kynurenine, N-A cetylaspartic acid, glyceric acid, adipic acid, citramalic acid, malic acid, isocitric acid, and oxoglutaric acid) and two clinical features (NT-proBNP and uric acid) were significantly associated with PerAF. Pathway enrichment analysis highlighted alterations in the citrate cycle and glyoxylate/dicarboxylate metabolism. XGBoost was chosen for establishing the final model since its predictive performance outperformed that of the other algorithms. The model based on clinical parameters, metabolites, and demographics achieved the highest AUC in both the discovery cohort (0.751 (95% CI [0.631~0.867])) and validation cohort (0.985 (95% CI [0.940~1.000])). A simplified model with three features (NT-proBNP, citramalic acid, and uric acid) retained robust performance. Conclusions: This study identified eight PerAF-related metabolites
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.